# Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

> **NCT04327700** · PHASE2 · TERMINATED · sponsor: **Wake Forest University Health Sciences** · enrollment: 2 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DEVICE:** TheraBionic
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT04327700
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-26
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Slow accruals
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04327700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04327700, "Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04327700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*